Business Context and Reporting Period
This Form 8-K Current Report was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on October 25, 2013. The report discloses the entry into a Material Definitive Agreement regarding a new equity financing program.
Key Financial Metrics and Transaction Details
- Transaction Type: At The Market Offering Agreement (Sales Agreement).
- Counterparty: T.R. Winston & Company, LLC (the Agent).
- Maximum Offering Size: Up to $20,000,000 in aggregate offering price of common stock.
- Compensation: The Company will pay the Agent a fee of 4.0% of the gross sales price of shares sold.
- Use of Proceeds: Net proceeds are intended for general corporate purposes.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or debt metrics. It is a disclosure of a contractual agreement.
Material Changes
The primary material change is the establishment of a flexible equity financing mechanism. The Company may now sell shares from time to time depending on market conditions through the Agent, either directly on the NYSE MKT, other trading markets, or via privately negotiated transactions. The Agent is not obligated to sell a specific number of shares.
Guidance, Outlook, and Risks
- Management Commentary: Management retains significant flexibility in applying the net proceeds from the offering.
- Market Dependency: Sales of shares are contingent upon market conditions and other factors determined by the Company.
- Legal Disclaimer: The report explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy shares in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $20 million offering.
- Review the Company's effective shelf registration statement (Form S-3, No. 333-190936) referenced in the filing.
- Examine the full text of the Sales Agreement (Exhibit 10.01) for specific termination provisions and conditions.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.